Edison Investment Research - IMPRIMIS PHARMACEUTICALS (IMMY) QuickView: Building revenue streams

Report

Edison Investment Research

QuickView: Building revenue streams

Imprimis is poised to achieve meaningful revenue in 2015. In 2014 it increased capacity by acquiring two compounding pharmacies and thus increased sales of its ophthalmic products. 2015 has seen continued adoption of the Dropless Therapy cataract surgery injection and the acquisition of the exclusive licence to Hep-Lido-A (HLA), which sold 80k units last year. Revenue is likely to rise in 2015, with strong upside potential if targeted increases in market share are achieved.

19/05/2015 2 EN

Underlying

IMPRIMIS PHARMACEUTICALS

Imprimis Pharmaceuticals is an ophthalmology-focused pharmaceutical company. The company's ophthalmology program consists of its proprietary Dropless Therapy

See profile

US45323A2015 United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

GlobeNewsWire

ImprimisRx to Introduce New Formulations at Cataract & Refractive Surgery Annual Meeting

ImprimisRx to Introduce New Formulations at Cataract & Refractive Surgery Annual Meeting Eleven relevant presentations are scheduled, covering all five ImprimisRx portfolios SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- ImprimisRx, the ophthalmology-focused pharmaceutical compounding subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its participation at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held at the San Diego Convention Center in San Diego, CA May 3-7, 2019. With an estimated 11,000 attendees expected, this is the largest...

April 30, 2019 April 30, 2019 1 EN

GlobeNewsWire

Harrow Health Announces Fourth Quarter 2018 Financial Results

Harrow Health Announces Fourth Quarter 2018 Financial Results SAN DIEGO, March 12, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the fourth quarter 2018. Fourth Quarter 2018 and Other Recent Notable Highlights: Revenues increased 55% year-over-year to a new record of $11.4 millionGross Ophthalmology revenue increased 72% year-over-year to a new record of $10 millionGross Margins hit a new record at 64%$18.1 million in Net Income (GAAP)ImprimisRx customers ordering chronic care ophthalmic medicines with refills expected to hit 1,000 by the end of ...

March 12, 2019 March 12, 2019 1 EN

GlobeNewsWire

Harrow Health to Attend 31st Annual ROTH Conference on March 18, 2019

Harrow Health to Attend 31st Annual ROTH Conference on March 18, 2019 SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019 at The Ritz Carlton, Laguna Niguel in Dana Point, CA. Mark L. Baum, the company’s Chief Executive Officer, and Andrew R. Boll, its Chief Financial Officer, will be hosting one-on-one meetings at the conference and attendees can contact their Roth Capital Partners representative to arrange a meeting. About Harrow Health Harrow Health, Inc. (NASDAQ:...

March 4, 2019 March 4, 2019 1 EN

Freelancer - AI to drive return to growth

Freelancer’s Q124 results were mixed. Operationally, the company is seeing rising demand for AI specialists as customers seek affordable ways to develop proprietary AI. Notably, in Enterprise, the company delivered a large-scale AI pilot for a tech giant, sourcing 20,000 freelancers in 24 hours across 52 languages. This impressive achievement could lead to a substantial multi-year contract. Major initiatives across Loadshift and Escrow with leading organisations are set to be deployed over the coming months, potentially catalysing performance and diversifying revenue streams. We revise our for...

1h / 40m 1h / 40m 1 EN

Toby Thorrington

Toby Thorrington

Renewi - Solid trading and better cash generation

Renewi’s FY24 trading update was in line with management’s expectations and its improved cash generation is reassuring for investors. Attention is now likely to turn the strategic review of the UK Municipals with management stating that they remain on track to update markets by the end of June. This could lead to an exit of key liabilities and leave Renewi as an attractive circular economy investment with strong market positions and organic growth plans, which should assist in generating value, including a potential re-rating of the shares.

1h / 43m 1h / 43m 1 EN

Richard Williamson

Richard Williamson

Filtronic - Agreement with SpaceX drives upgrades

Filtronic has signed a strategic partnership and commercial agreement with SpaceX which includes a production order worth £15.8m and warrants that could be exercised for up to 10% of existing share capital. Filtronic announced its first orders from SpaceX in January 2023, although the customer was unnamed at that point. Since then, SpaceX has placed orders totalling $43m (including yesterday’s order) for products to support the build out of its Starlink low Earth orbit (LEO) satellite constellation. The scale of these orders is such that we upgrade our forecasts, with the larger impact on FY25...

3h / 15m 3h / 15m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: Building revenue streams

ImprimisRx to Introduce New Formulations at Cataract & Refractive Surgery Annual Meeting

Harrow Health Announces Fourth Quarter 2018 Financial Results

Harrow Health to Attend 31st Annual ROTH Conference on March 18, 2019

Freelancer - AI to drive return to growth

Renewi - Solid trading and better cash generation

Filtronic - Agreement with SpaceX drives upgrades

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe